Physician profile
Evandro Silveira
NPI 1386672525
$1,600.63
in general payments reported to CMS, 2019-2025
20 companies · $146 in 2025
The $146 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $87.05 · 2021: $133 · 2022: $303 · 2023: $274 · 2024: $324 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $223.06 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $194.38 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $179.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $174.86 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $160.36 | 2019-2023 | |
| Glaxosmithkline, LLC. | $131.53 | 2020-2025 | Bexsero |
| Genzyme Corporation | $120.83 | 2024 | |
| Alk-Abello, INC | $72.47 | 2024 | Odactra, Ragwitek, Grastek |
| Genentech USA, INC. | $50.24 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $48.32 | 2025 | |
| Seqirus USA INC | $34.87 | 2022-2024 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $33.96 | 2020-2023 | |
| Tris Pharma INC | $33.71 | 2019-2024 | Dyanavel Xr |
| Kaleo, INC. | $28.60 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $23.95 | 2024 | Ycanth |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21.01 | 2023 | Flumist Quadrivalent |
| Sobi, INC | $18.91 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $18.91 | 2025 | Neffy |
| Noven Therapeutics, LLC | $16.99 | 2024 | Xelstrym |
| Shire North American Group INC | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evandro Silveira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.